Though AD remains a major public health problem, there are only two classes of pharmacologic therapy available for treating patients with AD, which include inhibitors to cholinesterase enzyme and antagonists to N-methyl-D-aspartate (NMDA). This evidence concerns the gene BCHE and Alzheimer disease.